Table 3. Randomized control trials for emerging drugs.
NCT ID: National Clinical Trial Identifier; oSOC: optimized standard of care; NET: neutrophil extracellular trap
| Intervention | NCT ID | No. of participants | Duration | Phase | Sponsor | ||
| Stem cells | |||||||
| Biological: PLX-PAD; biological: placebo | NCT04389450 | 140 | June 2020–September 2021 | Phase 2 | Pluristem Ltd. | ||
| Biological: MultiStem; biological: placebo | NCT04367077 | 400 | April 2020–August 2022 | Phase 2, phase 3 | Athersys, Inc | ||
| Targeting NETs | |||||||
| Drug: dornase alfa inhalation solution (Pulmozyme) | NCT04359654 | 50 | May 2020–November 2020 | Phase 2 | University College, London | ||
| Drug: anakinra 149 MG/ML prefilled syringe (Kineret) | NCT04443881 | 180 | May 2020–March 2021 | Phase 2, phase 3 | Fundacion Miguel Servet | ||
| Drug: anakinra plus oSOC; drug: oSOC | NCT04364009 | 240 | April 2020–September 2020 | Phase 3 | University Hospital, Tours | ||
| Drug: anakinra | NCT04341584 | 240 | April 2020–December 2020 | Phase 2 | Assistance Publique - Hôpitaux de Paris | ||
| Drug: standard treatment; drug: oral administration of colchicine plus herbal phenolic monoterpene fractions | NCT04392141 | 200 | April 2020–October 2020 | Phase 1, phase 2 | Kermanshah University of Medical Sciences | ||
| Drug: colchicine 1 MG oral tablet | NCT04375202 | 308 | April 2020–October 2020 | Phase 2 | University Of Perugia | ||
| Drug: colchicine; other: local standard of care | NCT04328480 | 2500 | April 2020–August 2020 | Phase 3 | Estudios Clínicos Latino América | ||
| Drug: colchicine plus symptomatic treatment (paracetamol); drug: symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations) | NCT04416334 | 1028 | May 2020–December 2020 | Phase 3 | Instituto de Investigación Marqués de Valdecilla | ||
| Drug: colchicine | NCT04322565 | 310 | April 2020–July 2020 | Phase 2 | Azienda Ospedaliero-Universitaria di Parma | ||
| Drug: colchicine; drug: placebo oral tablet | NCT04322682 | 6000 | March 2020–September 2020 | Phase 3 | Montreal Heart Institute | ||
| Darunavir | |||||||
| Drug: darunavir and cobicistat | NCT04252274 | 30 | January 2020–December 2020 | Phase 3 | Shanghai Public Health Clinical Center | ||
| Favipiravir | |||||||
| Drug: favipiravir; other: placebo | NCT04336904 | 100 | March 2020–July 2020 | Phase 3 | Giuliano Rizzardini | ||
| Drug: favipiravir; drug: standard of care | NCT04434248 | 330 | April 2020–July 2020 | Phase 2, phase 3 | Chromis LLC | ||
| Arbidol | |||||||
| Drug: carrimycin; drug: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate; drug: basic treatment | NCT04286503 | 520 | February 2020–February 2021 | Phase 4 | Beijing YouAn Hospital | ||
| Drug: Arbidol; other: basic treatment | NCT04260594 | 380 | February 2020–December 2020 | Phase 4 | Jieming QU | ||